孟鲁司特钠口服预防呼吸道合胞病毒毛细支气管炎后反复喘息及哮喘的效果分析

Effect analysis of oral montelukast sodium in preventing repeated wheeze and asthma after respiratory syncytial virus(RSV) bronchitis

目的探讨孟鲁司特钠口服预防呼吸道合胞病毒毛细支气管炎后反复喘息发作及哮喘的治疗方法并观察其短长期预防的临床疗效。方法按照自愿的原则,选取我院收治的140例呼吸道合胞病毒毛细支气管炎患儿,患者治愈后随机均分为观察组与对照组,观察组口服孟鲁司特钠1mg/次,1次/d,持续服药3个月;对照组不做处理。预防治疗后持续随访1.5年,观察孟鲁司特钠口服3个月对患儿反复喘息发作及哮喘的临床疗效。结果观察组在预防治疗3个月中,1例喘息及哮喘复发,而对照组复发4例;观察组的ECP、IL-8、NO显著低于对照组,无症状的平均天数显著高于对照组。1.5年内观察组哮喘、咳嗽的复发病例比率为34.29%(24/70),较对照组病情复发率低10%,无显著差异性(P>0.05)。结论孟鲁司特钠口服预防呼吸道合胞病毒毛细支气管炎后反复喘息发作及哮喘的方法短期疗效显著;而长期具有一定疗效,但疗效不显著。

Objective To explore the therapy of oral montelukast sodium in preventing repeated wheeze and asthma after respiratory syncytial virus （RSV） bronchitis and to observe its short-term and long-term clinical effect. Methods One hundred and forty children with RSV bronchitis in our hospital were chosen on the principle of voluntariness. All the 140 patients were randomly divided into two groups of equal number after they were completely cured： observation group and control group. Patients in the observation group prescriptions were orally administrated with 1 mg mon- telukast sodium once a day for three consecutive months, while patients in the control group were given no treatment. All the patients were followed up for 1.5 year after preventive treatment, observed the clinical effect of montelukast sodium orally administrated for 3 months on patients＇ repeated wheeze and asthma. Results During the three months＇ preventive treatment, only one patient in the observation group had the relapse of wheeze and asthma, while 4 patients in the control group has the relapse of wheeze and asthma; the ECP, IL-8 and NO of the observation group were significantly lower than those in the control group, and the average asymptomatic days of the observation group were significantly longer than those of the control group. In the 1.5 years＇ follow up period, the relapse rate of wheeze and asthma in the observation group was 34.29%（24/70）, lower than that in the control group （10%）. There was no significant difference between the two groups in the relapse rate （P〉0.05）. Conclusion The short-term clinical effect of oral montelukast sodium in preventing repeated wheeze and asthma after respiratory syncytial virus （RSV） bronchitis was significant; it also has long-term clinical effect, but the effect is insignificant.